Crews Matthieu P K, Howes Oliver D
South London and Maudsley NHS Foundation Trust, The Maudsley Hospital, Denmark Hill, London, SE5 8AZ, UK.
Hum Psychopharmacol. 2012 Jan;27(1):15-23. doi: 10.1002/hup.1265. Epub 2012 Jan 9.
Osteoporosis is increasingly common worldwide and there is a growing concern that the long-term use of antipsychotic medications increases the risk of this disorder. In this review, we consider whether antipsychotics may contribute to the development of osteoporosis through reductions in bone mineral density, discuss the possible mechanisms involved and consider the clinical implications of such a relationship.
We searched the literature for studies in this area published between 1966 and 2010 using the Medline and PubMed databases, supplemented by hand searches of retrieved reports.
The available data indicate that statistically significant reductions in bone mineral density are frequently seen in patients prescribed with antipsychotic medications and suggest that there is a higher incidence of clinically significant reductions compared with the normal population.
Clinicians should be aware for the potential negative effects of antipsychotic medications on bone mineral density, particularly in patients with additional risk factors for osteoporosis. Recommendations regarding routine monitoring of bone mineral density for patients prescribed antipsychotic medications cannot be made on the basis of existing evidence, and more research is required.
骨质疏松症在全球范围内日益普遍,人们越来越担心长期使用抗精神病药物会增加患这种疾病的风险。在本综述中,我们探讨抗精神病药物是否可能通过降低骨密度导致骨质疏松症的发生,讨论其中可能涉及的机制,并考虑这种关系的临床意义。
我们使用Medline和PubMed数据库检索了1966年至2010年间发表的该领域研究文献,并通过手工检索检索到的报告进行补充。
现有数据表明,服用抗精神病药物的患者经常出现具有统计学意义的骨密度降低,并且与正常人群相比,临床上显著降低的发生率更高。
临床医生应意识到抗精神病药物对骨密度的潜在负面影响,尤其是在有骨质疏松症其他危险因素的患者中。基于现有证据,无法就对抗精神病药物治疗患者进行骨密度常规监测提出建议,需要更多的研究。